Telehealth company maintains 2025 outlook, expands beyond GLP-1 offerings amid regulatory and partnership setbacks
Hims & Hers Health (HIMS) stock slid up to 5% on Tuesday after second-quarter revenue came in slightly below Wall Street expectations. The telehealth firm reported $544.8 million in revenue, a 73% jump from last year, but short of analysts’ $552 million forecast. Earnings per share, however, exceeded expectations at $0.17 versus $0.15. The company reaffirmed its full-year guidance of $2.3–$2.4 billion.
Shares dropped as much as 11% in premarket trading, following recent turbulence tied to its GLP-1 weight-loss drug offerings. In June, drugmaker Novo Nordisk (NVO) abruptly ended its partnership with Hims & Hers, alleging the company violated laws governing compounded drugs and engaged in misleading marketing.
The dispute comes after the U.S. FDA allowed compounding pharmacies to produce semaglutide-based drugs like Wegovy and Zepbound during shortages. Hims & Hers began marketing its own GLP-1 treatment in May 2024 but had to halt production after the FDA declared the shortage over in February 2025.
Despite regulatory headwinds, Hims & Hers continues to expand its portfolio. Management stated in May that the company’s goal is to grow from “hundreds of personalized treatments today to potentially thousands.”
CEO Andrew Dudum emphasized that the company’s growth reflects strong consumer demand for accessible, patient-focused care. “The momentum we saw through the first half of 2025 is proof that our platform is delivering exactly what millions of people have been waiting for,” Dudum said during the Q2 earnings call.
Hims & Hers stock remains up over 150% year-to-date, outperforming GLP-1 leaders Novo Nordisk—down more than 40%—and Eli Lilly, which is roughly flat. The company’s sustained growth suggests that its diversification strategy may help offset GLP-1 challenges in the months ahead.
You might like this article: Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom
